Publications by authors named "Yancy C"
Background: Black and Hispanic patients with heart failure (HF) have a higher risk of adverse clinical outcomes. Currently, it is unclear whether there are disparities in referral to outpatient HF management programs based on race and ethnicity.
Methods And Results: We used the American Heart Association GWTG-HF (Get With The Guidelines-Heart Failure) registry to examine 402 225 patients hospitalized for acute HF from January 1, 2010 to December 31, 2021.
Importance: Angiotensin receptor-neprilysin inhibition (ARNI) improves mortality among patients with heart failure with reduced ejection fraction (HFrEF), ie, those with an EF of 40% or less.
Objective: To describe national longitudinal trends in ARNI prescribing patterns among hospitalized patients with HFrEF.
Design, Setting, And Participants: Using data from the Get With The Guidelines-Heart Failure (GWTG-HF) registry, hospitalized patients with HFrEF at 614 participating hospitals were identified.
Background: Clinical guidelines recommend medications from four drug classes, collectively referred to as quadruple therapy, to improve outcomes for patients with heart failure with reduced ejection fraction (HFrEF). Wide gaps in uptake of these therapies persist across a range of settings. In this qualitative study, we identified determinants (i.
View Article and Find Full Text PDFAbstractIn response to the Covid-19 pandemic, the National Heart, Lung, and Blood Institute launched five multisite clinical trials testing candidate host tissue-directed medical interventions to hasten recovery, improve function, and reduce morbidity and mortality. Speed, flexibility, and collaboration were essential. This article from the Steering and Executive committees describes the Collaborating Network of Networks for Evaluating Covid-19 and Therapeutic Strategies (CONNECTS) research program that enrolled 6690 participants and evaluated 18 intervention strategies using 10 molecular agents across the care continuum (outpatient, inpatient, and post discharge), and reports lessons learned from this initiative.
View Article and Find Full Text PDFCardiovascular clinical trials continue to under-represent children, older adults, females and people from ethnic minority groups relative to population disease distribution. Here we describe strategies to foster trial representativeness, with proposed actions at the levels of trial funding, design, conduct and dissemination. In particular, trial representativeness may be increased through broad recruitment strategies and site selection criteria that reflect the diversity of patients in the catchment area, as well as limiting unjustified exclusion criteria and using pragmatic designs that minimize research burden on patients (including embedded and decentralized trials).
View Article and Find Full Text PDFArticle Synopsis
- The research highlights significant racial and ethnic disparities in excess mortality during the COVID-19 pandemic, revealing a concerning trend concerning minoritized populations who faced greater mortality rates compared to pre-pandemic disparities.!* -
- A comprehensive analysis of over 10.6 million death certificates from March 2020 to May 2023 indicated that more than 1.38 million excess deaths occurred, representing around 23 million years of potential life lost.!* -
- The findings emphasize the need for further investigation into the age-specific impact of COVID-19 on various racial and ethnic groups to better understand and address these health disparities moving forward.!*
Article Synopsis
- Home-time is the time patients spend alive and at home after being treated for heart failure, and it hasn't been studied much before. * -
- The study looked at 66,019 older patients who had heart failure from 2019 to 2021 and found that many didn’t get to spend all their time at home; only 22% spent a full year at home after leaving the hospital. * -
- A lot of older patients, especially Black patients, had less time at home, and many faced high rates of returning to the hospital or dying within a year after their discharge.*
Importance: Guideline-directed medical therapy (GDMT) remains underutilized on a global level, with significant disparities in access to treatment worldwide. The potential global benefits of quadruple therapy on patients with heart failure with reduced ejection fraction (HFrEF) have not yet been estimated.
Objective: To assess the projected population-level benefit of optimal GDMT use globally among patients with HFrEF.
Background: Few study authors examined factors influencing health-related quality of life (HRQOL) early after left ventricular assist device (LVAD) implantation.
Objective: The purpose of this study was to determine whether 5 novel self-report measures and other variables were significantly associated with overall HRQOL at 3 months after LVAD surgery.
Methods: Patients were recruited between October 26, 2016, and February 29, 2020, from 12 US sites.
Article Synopsis
- The review highlights a lack of evidence in coronary revascularization decisions specifically for women and minorities and introduces the RECHARGE trial program aimed at addressing this gap.
- The RECHARGE program includes two trials: one focused on women and the other on Black or Hispanic patients, comparing CABG and PCI treatments over a follow-up period of up to 10 years.
- Key outcomes will assess quality of life and mortality, with a focus on patient-centered measures, making these trials unique in their approach to these underrepresented populations.
Study Objective: The association of prior to admission guideline-directed medical therapy (GDMT) use in patients hospitalized with Heart Failure with Reduced Ejection Fraction (HFrEF, ejection fraction ≤40 %) and Coronavirus Disease 2019 (COVID-19) with in-hospital outcomes has not been well studied.
Design/setting/participants/interventions/outcome Measures: Using the American Heart Association's Get With The Guidelines Heart Failure Registry, we identified HFrEF patients presenting with acute decompensated heart failure (ADHF) and compared rates of GDMT prescription between those presenting prior to and during the pandemic. In a subgroup of patients with a concomitant COVID-19 diagnosis, we evaluated the association of prior to admission GDMT use with in-hospital mortality and severe COVID-19.
Article Synopsis
- Hypertension is a major risk factor for serious health conditions, and there’s potential for artificial intelligence (AI) to improve how it's diagnosed and managed.* -
- AI technologies, particularly machine learning, could personalize treatment and enhance blood pressure monitoring, but effective collaboration among health professionals and data scientists is crucial.* -
- A workshop by the National Heart, Lung, and Blood Institute highlighted communication gaps in healthcare, innovative methods for managing hypertension, and challenges to implementing AI in real-world settings.*